Alzheimer’s disease (AD) is the most common reason of progressive dementia in the elderly population. There has been an exponential rise in the number of cases of Alzheimer’s disease worldwide emphasizing the necessity for developing an effective treatment. According to Alzheimer’s Association, in 2016, an estimated 5.4 million Americans of all ages have Alzheimer's disease. One in nine people aged 65 and above has Alzheimer's disease. By 2050, the number of people aged 65 and above affected with Alzheimer's disease is expected to nearly triple, from 5.2 million to an expected 13.8 million, excluding the development of medical advances to avert or cure the disease. The mortality rates due to Alzheimer’s disease are quite high. Between 2000 and 2013, deaths due to heart disease, stroke and prostate cancer decreased 14%, 23% and 11%, respectively, while deaths from AD increased 71% in the U.S. Similarly, According to Alzheimer’s disease International in 2015, there are an estimated 46.8 million people worldwide living with dementia and is further expected to grow in future. Thus, there is an increasing in the demand for Alzheimer’s therapeutics and diagnostics worldwide.
Report Overview: https://www.transparencymarketresearch.com/alzheimers-disease-therapeutics-diagnostics-market.html
Population aging across the globe is a major factor driving the market for Alzheimer’s therapeutics and diagnostics. Rising life expectancy is contributing to quick increases in number of aged population, and is associated with increased prevalence of chronic diseases like dementia. Therapies for AD offer temporary and uncertain improvements in the well-being of individuals, and none of the approved drugs can modify the course of the disease advancement. Thus, the magnitude of the affected population and lack of suitable and effective treatment offers an incredible opportunity for drug manufacturers. However, identification of the primary reasons and mechanisms involved in AD are is limited. Drug manufacturers have been unable to validate significant clinical benefits of treatment for a numerous of new compounds due to strict regulations. One of the significant trend observed in this market is collaboration of the existing players. Precisely, diagnostic technology companies are carefully trying to bring about effective biomarker technologies to support and improve the drug development process for potential drug candidates which is further expected to propel the demand.
The Alzheimer’s disease Therapeutics and Diagnostics market has been segmented by therapeutics, diagnostics, imaging technologies and geography. The market by therapeutics includes biomarkers, Cholinesterase inhibitors and NMDA receptor antagonists. Based on diagnostics the market has been segmented as brain imaging and blood tests. The market by imaging technologies includes structural imaging, functional imaging and molecular imaging.
Geographically, the market has been segmented as North America, Europe, Asia Pacific, Latin America, Middle East & Africa and Rest of the World. North America was observed to be the largest market for Alzheimer’s disease Therapeutics and Diagnostics due to increasing prevalence of Alzheimer’s disease with rise in aging population, and extensive technological advancements in the region. With the increase in aging population developing region of Asia Pacific, this market is expected to grow at maximum rate during the forecast period. Developing countries are expected to offer lucrative opportunities for this market. According to Alzheimer’s disease International in 2015, 58% of people with dementia live in developing countries, but by 2050 this will rise to 68%. The fastest growth in the elderly population is taking place in China, India, and their south Asian and western Pacific region. According to World Alzheimer Report in 2015, regional estimations of dementia prevalence in people aged 60 years and over vary from 4.6% in Central Europe to 8.7% in North Africa and the Middle East, however all other regional estimates fall in a relatively between 5.6% and 7.6%.
Request Brochure: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=14675
The key manufacturers operating in the market are Abbvie Inc., AC Immune SA, Allergan PLC, Amarantus Bioscience Holdings, Anavex LifeSciences, Avid Radiopharmaceuticals, Axon Neuroscience, Axovant Sciences, Daiichi Sankyo Co, Eli Lilly, F. Hoffmann La Roche AG, GE Healthcare, Janssen Pharmaceuticals etc. They have applied strategies, such as mergers & acquisitions, partnerships, joint ventures, agreements, and others to have a strong foothold in the market.
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
Contact
Rohit Bhisey
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: [email protected]
Website: https://www.transparencymarketresearch.com/
We generally care for our friends and family particularly our senior people or parents.But we once in a while don't get enough an ideal opportunity for the consideration and backing for our elders.Its not on the grounds that we couldn't care less however we are having a bustling timetable in work or home.We once in a while don't confide in individuals to employ any house keepers for the minding of our kin.
Around then our administrations gave by senior care tampa and Elder consideration Tampa is valuable for the bustling planned individuals.
We give 24 hour in home consideration Tampa for the senior individuals and for their necessities.
The home consideration Tampa organization offers help and help for senior individuals and individuals experiencing hereditary disarranges or dementia and Alzheimer's.
Our cherishing and caring methodologies roll out a compelling improvement in patients' lives.
The alzheimers disease and dementia care tampa Services assists with diminishing the negative considering life and improve the desire to live.
